MX2019008496A - Aglutinantes de albumina serica mejorados. - Google Patents

Aglutinantes de albumina serica mejorados.

Info

Publication number
MX2019008496A
MX2019008496A MX2019008496A MX2019008496A MX2019008496A MX 2019008496 A MX2019008496 A MX 2019008496A MX 2019008496 A MX2019008496 A MX 2019008496A MX 2019008496 A MX2019008496 A MX 2019008496A MX 2019008496 A MX2019008496 A MX 2019008496A
Authority
MX
Mexico
Prior art keywords
serum albumin
relates
variable domains
improved serum
single variable
Prior art date
Application number
MX2019008496A
Other languages
English (en)
Spanish (es)
Inventor
Staelens Stephanie
Morizzo Erika
Steffensen Soren
Cerdobbel An
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2019008496A publication Critical patent/MX2019008496A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019008496A 2017-01-17 2018-01-17 Aglutinantes de albumina serica mejorados. MX2019008496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762446988P 2017-01-17 2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Publications (1)

Publication Number Publication Date
MX2019008496A true MX2019008496A (es) 2019-09-18

Family

ID=61521465

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008496A MX2019008496A (es) 2017-01-17 2018-01-17 Aglutinantes de albumina serica mejorados.
MX2023005374A MX2023005374A (es) 2017-01-17 2019-07-16 Aglutinantes de albumina serica mejorados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005374A MX2023005374A (es) 2017-01-17 2019-07-16 Aglutinantes de albumina serica mejorados.

Country Status (21)

Country Link
US (2) US11414481B2 (cg-RX-API-DMAC7.html)
EP (3) EP3571225B1 (cg-RX-API-DMAC7.html)
JP (3) JP7219220B2 (cg-RX-API-DMAC7.html)
KR (2) KR102662499B1 (cg-RX-API-DMAC7.html)
CN (2) CN110191896B (cg-RX-API-DMAC7.html)
AU (2) AU2018209151B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014599A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050575A1 (cg-RX-API-DMAC7.html)
DK (1) DK3571225T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991459T3 (cg-RX-API-DMAC7.html)
FI (1) FI3571225T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241469T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068790T2 (cg-RX-API-DMAC7.html)
IL (2) IL312292A (cg-RX-API-DMAC7.html)
LT (1) LT3571225T (cg-RX-API-DMAC7.html)
MX (2) MX2019008496A (cg-RX-API-DMAC7.html)
PT (1) PT3571225T (cg-RX-API-DMAC7.html)
RS (1) RS66117B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201906264YA (cg-RX-API-DMAC7.html)
SI (1) SI3571225T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018134235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL250396B (en) 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
US11414481B2 (en) * 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
LT3571224T (lt) * 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
IL293554A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising an immunoglobulin with one variable domain that target tnfa and ox40l
KR20220123237A (ko) 2019-12-09 2022-09-06 아블린쓰 엔.브이. Il-13 및 tslp를 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩타이드
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
IL296767A (en) 2020-03-30 2022-11-01 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
JP2023544124A (ja) 2020-09-25 2023-10-20 アブリンクス エン.ヴェー. Il-13およびox40lを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
US11897951B2 (en) * 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
JP2024546916A (ja) 2021-12-17 2024-12-26 アブリンクス エン.ヴェー. TCRαβ、CD33及びCD123を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
JP2025526384A (ja) 2022-07-27 2025-08-13 アブリンクス エン.ヴェー. 新生児型Fc受容体の特異的エピトープに結合するポリペプチド
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드
TW202444757A (zh) 2023-03-14 2024-11-16 美商奧迪希治療公司 抗cd25抗原結合蛋白及其用途
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
KR102822958B1 (ko) * 2023-05-23 2025-06-20 대한민국(해양경찰청 해양경찰연구센터장) 고래 불법포획 감식용 신속진단키트
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525843A (zh) 2023-09-04 2025-07-01 法商賽諾菲公司 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025217488A1 (en) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
CN100439400C (zh) 2003-01-10 2008-12-03 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US20090191217A1 (en) 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
DK1888641T3 (da) 2005-05-18 2012-04-23 Ablynx Nv Serumalbuminbindende proteiner
BRPI0609797B8 (pt) 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
TW200730539A (en) 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
AU2006321367B2 (en) 2005-12-01 2011-11-03 Domantis Limited Competitive domain antibody formats that bind Interleukin 1 Receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110189203A1 (en) 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
BR112012001681A2 (pt) 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
CN104147611A (zh) 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
WO2012020143A1 (en) 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
EP2606065A2 (en) 2010-08-20 2013-06-26 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2759936T3 (es) * 2011-06-23 2020-05-12 Ablynx Nv Proteínas de unión a albúmina sérica
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2944654A1 (en) * 2011-06-23 2015-11-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
IL250396B (en) * 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
KR102162413B1 (ko) 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
DK3143042T3 (da) 2014-05-16 2020-08-31 Ablynx Nv Forbedrede variable immunoglobulindomæner
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
DK3294768T3 (da) 2015-05-13 2019-11-11 Ablynx Nv T-celle-rekrutterende polypeptider baseret på tcr-alfa/beta-reaktivitet
PL3374392T3 (pl) * 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
JP7256011B2 (ja) 2015-11-27 2023-04-11 アブリンクス エン.ヴェー. Cd40lを阻害するポリペプチド
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
LT3571224T (lt) * 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
WO2025061919A1 (en) * 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders

Also Published As

Publication number Publication date
JP7219220B2 (ja) 2023-02-07
KR20240013861A (ko) 2024-01-30
ES2991459T3 (es) 2024-12-03
US20230060574A1 (en) 2023-03-02
WO2018134235A8 (en) 2024-03-21
MX2023005374A (es) 2023-05-22
FI3571225T3 (fi) 2024-10-31
SI3571225T1 (sl) 2025-03-31
RU2019125831A (ru) 2021-02-19
RS66117B1 (sr) 2024-11-29
AU2018209151A1 (en) 2019-07-25
EP4442709A2 (en) 2024-10-09
EP4442709A3 (en) 2024-12-25
US11414481B2 (en) 2022-08-16
JP2023025232A (ja) 2023-02-21
KR20190104608A (ko) 2019-09-10
EP4442707A3 (en) 2024-12-25
CN110191896B (zh) 2023-09-29
KR102662499B1 (ko) 2024-05-02
IL267894B1 (en) 2024-06-01
WO2018134235A1 (en) 2018-07-26
US20190367597A1 (en) 2019-12-05
LT3571225T (lt) 2024-11-11
SG10202108972RA (en) 2021-09-29
CA3050575A1 (en) 2018-07-26
AU2025203430A1 (en) 2025-06-05
RU2019125831A3 (cg-RX-API-DMAC7.html) 2021-03-09
AU2018209151B2 (en) 2025-02-27
PT3571225T (pt) 2024-11-05
HUE068790T2 (hu) 2025-01-28
CN110191896A (zh) 2019-08-30
EP4442707A2 (en) 2024-10-09
IL312292A (en) 2024-06-01
CN117285623A (zh) 2023-12-26
IL267894B2 (en) 2024-10-01
DK3571225T3 (da) 2024-11-04
IL267894A (en) 2019-09-26
EP3571225A1 (en) 2019-11-27
JP2020515518A (ja) 2020-05-28
HRP20241469T1 (hr) 2025-01-03
BR112019014599A2 (pt) 2020-03-03
JP2025026992A (ja) 2025-02-26
EP3571225B1 (en) 2024-08-07
SG11201906264YA (en) 2019-08-27
JP7628996B2 (ja) 2025-02-12

Similar Documents

Publication Publication Date Title
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2024008521A (es) Aglutinantes de albumina serica mejorados.
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
WO2017085172A3 (en) Improved serum albumin binders
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
PH12018501025A1 (en) Improved tnf binders
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
BR112018070998A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
EA201890613A1 (ru) Полипептиды, связывающие cd3
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2016172551A3 (en) Methods of identifying bacteria comprising binding polypeptides
HK1258507A1 (zh) 改进的p2x7受体结合剂和包含其的多肽
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
EA202090617A1 (ru) Варианты антител
EA202090727A1 (ru) Варианты антител
TH148296B (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)
EA201990773A1 (ru) Cd123-связывающие белки и относящиеся к ним композиции и способы
TN2018000345A1 (en) Trispecific and/or trivalent binding proteins